A personalized medicine cancer research study
Key leaders of the new genetic-screening research program include Dana-Farber’s Barrett Rollins, MD, PhD, and Neal Lindeman, MD, of Brigham and Women’s Hospital.
Profile, a research project launched by scientists at Dana-Farber Cancer Institute and Brigham and Women's Hospital, is one of the nation's most comprehensive personalized cancer medicine initiatives. Since the project began in 2011, Profile scientists have been analyzing the DNA in tumor tissue from patients coming to Dana-Farber Cancer Institute and Brigham and Women's Hospital for treatment of all types of cancers. Subsequently, Profile testing has expanded to pediatric cancer patients at Boston Children's Hospital.
Every patient's cancer contains a specific pattern of DNA mutations and other alterations — called a "tumor profile" — that can potentially be used to select regimens of cancer therapies for individual patients. With Profile, scientists are creating one of the world's largest databases on the genetic abnormalities that drive the development of tumors, as well as advancing the goals of personalized, precision cancer care.
More than 43,000 patients have consented to have tumor tissue analyzed for the presence of mutations and other cancer-related DNA abnormalities. Since its inception, Profile has completed more than 22,000 genetic profiles of patients' tumors, adding about 400 each month to the database.
In a new phase of Profile, begun in 2013, a technology known as "massively parallel" or "next-generation" sequencing, reads the genetic code of approximately 300 genes in each tumor sample. "Massively parallel" refers to the technology's capacity for sequencing large numbers of genes simultaneously. These genes were chosen because they have been implicated in a variety of cancers. In October 2016, version 3 of was launched, with an assay that interrogates 447 genes.
Called OncoPanel, this advanced sequencing platform is an important update to the original OncoMap platform. OncoPanel can detect not only genetic mutations, but also other critical types of cancer-related DNA alterations. Whereas OncoMap was limited to screening for known mutations, OncoPanel can discover new ones not previously identified.
The genotyping or "genetic profiling" studies are performed on samples of solid tumors, bone marrow, or blood specimens to identify the specific mutations and other DNA alterations driving a patient's cancer. The OncoPanel testing is done at the Center for Advanced Molecular Diagnostics, a CLIA-certified laboratory in the Department of Pathology at Brigham and Women's Hospital.